2020 Shortlist review

Back | Best Communication Award | Breakthrough of the Year AwardBest Technology Award
Mediscience Commentator of the Year Award | Capital Market Transaction of the Year Award
Most Significant Contribution to the Mediscience Sector AwardThe Emerging Star Award
Chief Executive of the Year Award | Company of the Year Award 


Most Significant Contribution 
to the Mediscience Sector Award

Sponsored by Covington 

Criteria 

The winner of this award could be an individual, a company, a government department, research council, etc. who has made the single, biggest, most significant contribution to the sector. Difficult to define, but the Voting Panel will be aware of, and make allowances for, this fact.

The 2020 finalists:  


EMA20_Shortlist-contribution_S.Bates_BIA.png

STEVE BATES/BIA

www.bioindustry.org

Steve Bates has been CEO of the UK BioIndustry Association since 2012. He also chairs the International Council of Biotech Associations and has been a board member of Europabio since 2015. Steve is the visible force of the vibrant UK life sciences industry to government and media.

Steve was described by the Voting Panel as “an absolute power-house” who has relentlessly lobbied and campaigned with positive results. One such example: in February this year, Steve convened a group to address the problem of Covid-19 vaccine scale-up and delivery. Within one month, the UK had a "coalition of the willing" with credible plans to supply 100m vaccine doses to the UK and beyond.

An expert and regular commentator on the sector in the media and at conferences, Steve has worked both in biotech and at the highest levels of UK government for over 15 years.

 
EMA20_Shortlist-contribution_C.Cookson_FT.png

Clive Cookson/Financial Times

www.ft.com

Previous winner of the European Mediscience Commentator of the Year Award, Clive is the FT’s Science Editor, covering the field of science, spanning medicine, space and research policy. Clive also guides the coverage of science in the FT, discussing key policy issues, from R&D funding to science education.

Clive has worked in science journalism for the entire duration of his career. His commitment to the sector was commended by the Voting Panel and his expertise in his field is unrivalled. Clive shines a light on unique science in an accessible way and his passion for the sector is consistently evident.

Prior to the FT, Clive worked previously as Science Correspondent for BBC Radio.

 
EMA20_Shortlist-contribution_EIB.png

EUROPEAN INVESTMENT BANK 

www.eib.org

EIB is the lending arm of the European Union. It is the biggest multilateral financial institution in the world and one of the largest providers of climate finance. EIB also has a share in the European Investment Fund (EIF), which invests in SMEs.EIB’s current pipeline of projects in the health sector amounts to around €5bn. The bank’s Infectious Disease Finance Facility also committed over €300m in the first quarter of this year alone. The Voting Panel were particularly impressed with EIB’s swift response to Covid-19, which was strategic and determined and involved funding the development of effective therapies, novel vaccines and diagnostics.

EIB’s reach across the sector has been extensive and its investment, in many cases, has been transformative.

 
EMA20_Shortlist-contribution_Strungmann-brothers.png

ANDREAS AND THOMAS STRUNGMANN 

www.bioeq.com

Andreas and Thomas Strüngmann have been writing the history of the German pharmaceutical industry since 1979. The twin brothers invest in biotech, pharma, life sciences and healthcare companies and their portfolio includes BioNTech and AiCuris.

The Strüngmann’s have been on a long and successful journey in the healthcare sector, starting with co-founding Hexal in 1986. They later sold their generic drugmaker Hexal (plus a stake in Eon Labs) to Novartis for some $7bn and have continued to fund breakthrough science and innovative biomedicines. The Strüngmann brothers have built an impressive portfolio of biotechnology leaders such Mega Pharma and BioNtech, culminating in its IPO in 2019.

In 2008, The Strüngmann’s established a neuroscience research centre in Frankfurt named after their father.